fda bpc 157 not approved for human use This is the first vote from the FDA's Pharmacy Compounding Advisory Committee on one of 7 peptides up consideration. While the committee advises through these votes, ultimately the will make FDA reviews BPC-157, TB-500 and

The pharmaceutical industry abandoned oral peptide development for decades specifically because of these challenges

In a case of first impression, Equity Partner Daniel Karp, with the assistance of Michael Eady, convinced the Texas Supreme Court that placing a burden on a common shipper would not only be new law but would contradict many of the guiding principles of tort responsibility in Texas

The use of botulinum toxin in rosacea treatment may provide temporary relief by reducing blood vessel dilation

And while Reblozyl was previously only available to patients exhibiting ring sideroblastsblood cells with iron deposits circling the nucleusit is now approved to treat those with and without this common symptom